J Schlom

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Exercise enhances vaccine-induced antigen-specific T cell responses
    Connie J Rogers
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Vaccine 26:5407-15. 2008
  2. ncbi Therapeutic cancer vaccines: current status and moving forward
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm 8B09, Bethesda, MD 20892, USA
    J Natl Cancer Inst 104:599-613. 2012
  3. ncbi A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines
    J Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Artif Cells Blood Substit Immobil Biotechnol 31:193-228. 2003
  4. ncbi Cancer vaccines: moving beyond current paradigms
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:3776-82. 2007
  5. ncbi Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation
    J Schlom
    Laboratory of Tumour Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Dev Biol (Basel) 116:27-47. 2004
  6. ncbi The diversity of T-cell co-stimulation in the induction of antitumor immunity
    J Schlom
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda MD 20892 1750, USA
    Immunol Rev 170:73-84. 1999
  7. ncbi Paradigm shifts in cancer vaccine therapy
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, CCR, NCI, 10 Center Drive, Room 8B09, Bethesda, MD 20892, USA
    Exp Biol Med (Maywood) 233:522-34. 2008
  8. ncbi Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules
    J W Hodge
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Building 10, Room 8B07, 10 Center Drive, Bethesda, MD 20892-1750, USA
    Vaccine 19:3552-67. 2001
  9. ncbi Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant
    E Kass
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 61:206-14. 2001
  10. ncbi The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells
    K Y Tsang
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 61:7568-76. 2001

Detail Information

Publications96

  1. ncbi Exercise enhances vaccine-induced antigen-specific T cell responses
    Connie J Rogers
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Vaccine 26:5407-15. 2008
    ..These results suggest that coupling moderate exercise with vaccination may enhance vaccine efficacy for the prevention and/or therapy of numerous diseases...
  2. ncbi Therapeutic cancer vaccines: current status and moving forward
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm 8B09, Bethesda, MD 20892, USA
    J Natl Cancer Inst 104:599-613. 2012
    ..The potential influence of the appropriate patient population and clinical trial endpoint in vaccine therapy studies is discussed, as well as the potential importance of biomarkers in future directions of this field...
  3. ncbi A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines
    J Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Artif Cells Blood Substit Immobil Biotechnol 31:193-228. 2003
    ..In vivo, peptide-pulsed DCs infected with TRICOM vectors induced cytotoxic T lymphocyte activity markedly and significantly greater than peptide-pulsed DCs...
  4. ncbi Cancer vaccines: moving beyond current paradigms
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:3776-82. 2007
    ..Consequently, evidence is emerging from several studies in which patient cohorts who first receive a cancer vaccine (as contrasted with control cohorts) benefit clinically from subsequent therapies...
  5. ncbi Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation
    J Schlom
    Laboratory of Tumour Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Dev Biol (Basel) 116:27-47. 2004
  6. ncbi The diversity of T-cell co-stimulation in the induction of antitumor immunity
    J Schlom
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda MD 20892 1750, USA
    Immunol Rev 170:73-84. 1999
    ....
  7. ncbi Paradigm shifts in cancer vaccine therapy
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, CCR, NCI, 10 Center Drive, Room 8B09, Bethesda, MD 20892, USA
    Exp Biol Med (Maywood) 233:522-34. 2008
    ..The unique features of this modality require the consideration of paradigm shifts both in the way cancer vaccine clinical trials are designed and in the way patient benefit is evaluated...
  8. ncbi Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules
    J W Hodge
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Building 10, Room 8B07, 10 Center Drive, Bethesda, MD 20892-1750, USA
    Vaccine 19:3552-67. 2001
    ....
  9. ncbi Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant
    E Kass
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 61:206-14. 2001
    ....
  10. ncbi The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells
    K Y Tsang
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 61:7568-76. 2001
    ....
  11. ncbi Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells
    M Zhu
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892-1750, USA
    Cancer Res 61:3725-34. 2001
    ..The use of this approach for in vitro studies and clinical applications in immunotherapy is discussed...
  12. ncbi Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors
    A N Rad
    Howard Hughes Medical Institute, Research Scholar's Program at the National Institutes of Health, Bethesda, MD 20892, USA
    Crit Rev Oncol Hematol 39:43-57. 2001
    ..APCs infected with TRICOM vectors are shown to significantly enhance the activation of both naive and effector CD4(+) and CD8(+) T-cell populations. The use of TRICOM vectors in vaccine strategies is discussed...
  13. ncbi Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects
    D W Grosenbach
    Laboratory of Tumor Immunology and Biology, National Cancer Institute/NIH, Bethesda, MD 20892-1750, USA
    Cancer Res 61:4497-505. 2001
    ....
  14. ncbi Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3)
    P Shankar
    Research Scholar's Program at the NIH, Howard Hughes Medical Institute, Bethesda, MD 20892, USA
    Vaccine 20:744-55. 2001
    ..The ability to augment immune responses using poxvirus-based vaccines containing multiple costimulatory molecule transgenes can now be addressed in the rhesus macaque model...
  15. ncbi Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity
    Wilhelmina M Aarts
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 62:5770-7. 2002
    ....
  16. ncbi Rational antigen modification as a strategy to upregulate or downregulate antigen recognition
    S I Abrams
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Curr Opin Immunol 12:85-91. 2000
    ....
  17. ncbi Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations
    Amanda L Boehm
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:397-408. 2010
    ..We hypothesize here that two vaccine platforms targeting the same antigen might induce shared and distinct antigen-specific T-cell populations, and examined the possibility that two distinct vaccines could be used concomitantly...
  18. ncbi Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:3060-9. 2008
    ..Carcinoembryonic antigen (CEA) and MUC-1 are overexpressed in a substantial proportion of common solid carcinomas. The primary end point of this study was vaccine safety, with immunologic and clinical responses as secondary end points...
  19. ncbi Acquisition of CD80 (B7-1) by T cells
    H Sabzevari
    Laboratory of Tumor Immunology and Biology, Division of Basic Sciences, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 166:2505-13. 2001
    ..Thus we demonstrate both immunostimulatory and immunoregulatory functions as a result of CD80 acquisition by different T cell populations...
  20. ncbi Vaccine therapy of established tumors in the absence of autoimmunity
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-1750, USA
    Clin Cancer Res 9:1837-49. 2003
    ..These studies thus demonstrate that a balance can indeed be achieved between the induction of an immune response to a self-antigen, which is capable of antitumor therapy, and the absence of autoimmunity...
  21. ncbi Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells
    Mary T Litzinger
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leuk Res 34:1351-7. 2010
    ..This study supports the rationale for the use of CLL cells modified ex vivo with pre-specified recombinant MVA vectors as a whole tumor-cell vaccine for immunotherapy in CLL patients...
  22. ncbi Selective induction of high avidity CTL by altering the balance of signals from APC
    SangKon Oh
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:2523-30. 2003
    ..Our data also suggested that dendritic cells play an important role in induction of high avidity CD8(+) CTL in vivo. This strategy to selectively induce higher avidity CTL may lead to more effective vaccines for viruses and cancer...
  23. ncbi Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity
    Chie Kudo-Saito
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Cancer Immunol Immunother 56:1897-910. 2007
    ..These studies demonstrate for the first time that the level and avidity of antigen specific CTL, as well as the therapeutic outcome can be improved with the use of i.t. rF-IL-2 with vaccine regimens...
  24. ncbi Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells
    Sixun Yang
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:5603-15. 2005
    ..To our knowledge, these studies are the first to show a methodology to induce higher-avidity human CTLs and have implications for the development of more efficient vaccines for a range of human cancers...
  25. ncbi Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49
    S V Kashmiri
    National Institutes of Health, National Cancer Institute, Laboratory of Tumor Immunology and Biology, Building 10, Room 5B38, Bethesda, MD 20892, USA
    Crit Rev Oncol Hematol 38:3-16. 2001
    ....
  26. ncbi Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells
    Claudia Palena
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 104:192-9. 2004
    ..Ex vivo-generated antigen-specific T cells activated in this manner might be applied to experimental protocols or used for adoptive transfer in immunotherapy protocols...
  27. ncbi Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute/NIH, Building 10, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Res 63:7942-9. 2003
    ....
  28. ncbi TRICOM vector based cancer vaccines
    Charlie T Garnett
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute/NIH, Bldg. 10, Rm. 8B09, 10 Center Drive, Bethesda, MD 20892, USA
    Curr Pharm Des 12:351-61. 2006
    ..In this article, preclinical findings and recent clinical applications of TRICOM-based vaccines as a cancer immunotherapy are reviewed...
  29. ncbi Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules
    Kwong Y Tsang
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 11:1597-607. 2005
    ..CONCLUSION: These studies provide the rationale for the clinical evaluation of these multigene vectors in patients with a range of carcinomas expressing MUC-1 and/or CEA...
  30. ncbi Multiple costimulatory modalities enhance CTL avidity
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:5994-6004. 2005
    ..The results reported in this study thus demonstrate multiple strategies that can be used in both antitumor and antiviral vaccine settings to generate higher avidity host T cell responses...
  31. ncbi A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production
    Douglas W Grosenbach
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 8B09, Bethesda, MD 20892 1750, USA
    Cell Immunol 222:45-57. 2003
    ....
  32. ncbi Clinical safety of a viral vector based prostate cancer vaccine strategy
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 178:1515-20. 2007
    ....
  33. ncbi Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant
    Robert J Lechleider
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 14:5284-91. 2008
    ..We hypothesized that a "metronomic" dose of interleukin 2 (IL-2) as a biological adjuvant would cause less toxicity while maintaining immunologic response...
  34. ncbi Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:663-74. 2010
    ..This hypothesis-generating study provides evidence that patients with more indolent mCRPC (Halabi predicted survival > or =18 months) may best benefit from vaccine therapy...
  35. ncbi New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy
    Vittore Cereda
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:63-71. 2010
    ..These studies thus identify NGEP as a potential target for T cell-mediated immunotherapy of prostate cancer...
  36. ncbi Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity
    John W Greiner
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 62:6944-51. 2002
    ..The CEA.Tg/MIN mice present a clinically relevant model in which different CEA-based vaccine strategies can be tested on the spontaneous onset of intestinal tumorigenesis...
  37. ncbi Clinical trial designs for the early clinical development of therapeutic cancer vaccines
    R M Simon
    Branch of Biometric Research, Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7434, USA
    J Clin Oncol 19:1848-54. 2001
    ..Several conclusions for expediting the clinical development of effective cancer vaccines are proposed...
  38. ncbi Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice
    Hasan E Zeytin
    Laboratories of Tumor Immunology and Biology, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 64:3668-78. 2004
    ....
  39. ncbi Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 27:4475-82. 2009
    ..The studies reported here show for the first time that priming with rMVA followed 7 days later by an rF boost at the same injection site, versus a distal site, generates superior tumor-specific immunity and antitumor activity...
  40. ncbi 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
    Chie Kudo-Saito
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 24:4975-86. 2006
    ..The inclusion of costimulatory molecules targeting distinct T cell signaling pathways provides a mechanism for enhancing the therapeutic effectiveness of tumor vaccines...
  41. ncbi Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells
    Sixun Yang
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 58:503-15. 2009
    ..Results indicated that enhanced costimulation greatly expanded human CEA-specific CD8(+) T cells and enhanced T-cell function, without inducing increased apoptosis of CEA-specific memory CD8(+) T cells...
  42. ncbi Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2
    Chie Kudo Saito
    Laboratories of Tumor Immunology and Biology and Experimental Immunology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 13:1936-46. 2007
    ....
  43. ncbi Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells
    Michael B Bernstein
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 26:509-21. 2008
    ..Thus, these studies taken together form a scientific rationale for the use of recombinant yeast in vaccination protocols for cancer or infectious diseases...
  44. ncbi A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892-1750, USA
    Clin Cancer Res 12:1260-9. 2006
    ..Larger prospective clinical studies will be required to validate these findings...
  45. ncbi Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy
    Dale C Slavin-Chiorini
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Gene Ther 11:665-80. 2004
    ..These studies thus support the concept of intratumoral vaccination employing vectors expressing costimulatory molecules...
  46. ncbi IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines
    E Reali
    San Raffaele Scientific Institute, Milan, Italy
    Cancer Res 61:5517-22. 2001
    ..This suggests a potential role for IgEs in the design of new cell-based tumor vaccines...
  47. ncbi Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice
    Connie J Rogers
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Nutr 138:115-22. 2008
    ..05). These data suggest that ER and EX enhance some, but not all, components of the immune system and are likely working via different biological mechanisms to regulate NK and T-cell function...
  48. ncbi Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules
    Chie Kudo-Saito
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute/NIH, 10 Center Drive, Room 8B09, Bethesda, MD 20892, USA
    Clin Cancer Res 10:1090-9. 2004
    ..CONCLUSIONS: These studies demonstrate that the diversified vaccine regimens that consisted of s.c. prime and i.t. boosts with CEA/TRICOM vectors could induce antitumor therapy superior to that seen by either route alone...
  49. ncbi Cancer vaccines: preclinical studies and novel strategies
    Claudia Palena
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Adv Cancer Res 95:115-45. 2006
    ..The results from these studies would certainly support the development of new vaccination strategies toward cancer vaccines with enhanced clinical efficacy...
  50. ncbi The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines
    Kenneth W Hance
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:2387-96. 2009
    ....
  51. ncbi Vaccines with enhanced costimulation maintain high avidity memory CTL
    Sixun Yang
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:3715-23. 2005
    ..These studies thus have implications in the design of more effective vaccine strategies...
  52. ncbi Costimulatory molecules as adjuvants for immunotherapy
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Front Biosci 11:788-803. 2006
    ..This review will focus on the current state of the use of costimulatory molecules as adjuvants for immunotherapy, and in particular, as immunomodulators for cancer vaccines...
  53. ncbi The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses
    Mala Chakraborty
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive Room 8B09, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 56:1471-84. 2007
    ..These studies also underscore the importance of "drug" scheduling in vaccine combination therapies...
  54. ncbi Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer
    Philip M Arlen
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Expert Rev Vaccines 2:483-93. 2003
    ..Newer approaches incorporating costimulatory molecules that enhance Tcell activation are also being investigated...
  55. ncbi Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement
    Charlie T Garnett
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 14:3536-44. 2008
    ....
  56. ncbi Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Crit Rev Immunol 27:451-62. 2007
    ..In addition, clinical studies combining vaccines with radiation therapy, chemotherapy, and second-line hormone therapy have provided preliminary evidence of prolongation of time to disease progression and antigen cascade postvaccination...
  57. ncbi Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer
    James Gulley
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Prostate 53:109-17. 2002
    ..New PSA-based vaccines and vaccine strategies are currently being evaluated...
  58. ncbi Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses
    Chie Kudo-Saito
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute/NIH, Building 10, Bethesda, MD 93042, USA
    Clin Cancer Res 11:2416-26. 2005
    ..CONCLUSION: These studies show that the breadth and magnitude of antitumor immune cascades to multiple antigens could be critical in the therapy of established tumors...
  59. ncbi Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Medical Oncology Clinical Research Unit, Radiation Oncology Branch, and Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:3353-62. 2005
    ..CONCLUSION: This vaccine regimen can be safely given in patients undergoing radiation therapy for localized prostate cancer, with the majority of patients generating a PSA-specific cellular immune response to vaccine...
  60. ncbi Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Detect Prev 26:275-91. 2002
    ....
  61. ncbi Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide
    E Salazar
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Int J Cancer 85:829-38. 2000
    ....
  62. ncbi Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer
    Marc R Theoret
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Genitourin Cancer 5:347-50. 2007
  63. ncbi Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses
    Elizabeth K Wansley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:4316-25. 2008
    ..cerevisiae construct expressing human CEA (yeast-CEA) elicits CEA-specific T-cell responses and antitumor activity...
  64. ncbi A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy
    John C Morris
    Metabolism Branch, Laboratory of Pathology, Department of Laboratory Medicine, National Eye Institute, Bethesda, MD 20892 1457, USA
    Clin Cancer Res 13:958-64. 2007
    ..The primary end point was to determine drug toxicity. Tumor response, tumor-specific CD8+ T-cell immune responses, and modulation of CD4+ CD25+ FoxP3+ regulatory T-cell (Treg) numbers were secondary end points...
  65. ncbi Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy
    Ravi A Madan
    Laboratory of Tumor Immunology and Biology, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:4526-31. 2008
    ..We now report survival analyses at 6.5 years from the initiation of therapy with a median potential follow-up of 4.4 years...
  66. ncbi Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients
    Mary T Litzinger
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 58:955-65. 2009
    ..Given the immunodeficiencies characteristic of CLL, enhancing the antigen-presenting function of CLL cells and T cells simultaneously could be a distinct advantage in the effort to elicit antitumor immune responses...
  67. ncbi Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 174:539-46. 2005
    ..9 months from initiation of therapy. CONCLUSIONS: Further studies are merited to investigate the role of combining vaccine with antiandrogen therapy or vaccine followed by vaccine plus antiandrogen therapy in this patient population...
  68. ncbi The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells
    Romaine I Fernando
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 120:533-44. 2010
    ..The selective expression of Brachyury in tumor cells and its role in EMT and cancer progression suggest that Brachyury may be an attractive target for antitumor therapies...
  69. ncbi Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine
    Benedetto Farsaci
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 127:1603-13. 2010
    ..It is also the first to demonstrate the efficacy of this sequence in reducing tumors in mouse models, providing a rationale for the design of combinational clinical studies...
  70. ncbi Vaccines as monotherapy and in combination therapy for prostate cancer
    Julia Rotow
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Clin Transl Sci 3:116-22. 2010
    ....
  71. ncbi The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors
    Chie Kudo-Saito
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:4533-44. 2005
    ..CONCLUSIONS: These studies reported here support the rationale for clinical trials employing multimodal immune-based therapies...
  72. ncbi Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen
    S Zaremba
    Laboratory of Tumor Immunology and Biology, Division of Basic Sciences, National Cancer Institute, Bethesda, Maryland 20892 1750, USA
    Cancer Res 57:4570-7. 1997
    ..Most importantly, these CTLs were capable of lysing human tumor cells endogenously expressing CEA. The use of enhancer agonist CTL peptides may thus represent a new efficient direction for immunotherapy protocols...
  73. ncbi Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses
    K Uzendoski
    Howard Hughes Medical Institute Research Scholars Program at the NIH, Bethesda, MD 20892 1750, USA
    Hum Gene Ther 8:851-60. 1997
    ..These studies demonstrated the utility of a recombinant vaccinia virus to deliver and efficiently express ICAM-1 molecules on tumor cells for potential gene therapy and recombinant approaches to cancer immunotherapy...
  74. ncbi Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms
    E Reali
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 23:2909-21. 2005
    ..The study underscores the importance of defining the appropriate delivery form of an immune adjuvant, such as GM-CSF, relative to the immunization strategy to maximize the host immune responses against a specific antigen...
  75. ncbi External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing
    Mala Chakraborty
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Res 64:4328-37. 2004
    ..Thus, these studies demonstrate a new paradigm for the use of local tumor irradiation in combination with active specific vaccine therapy to elicit durable antitumor responses of established tumors...
  76. ncbi Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules
    Claudia Palena
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 106:3515-23. 2005
    ..Therefore, our findings suggest that the use of CLL cells infected ex vivo with MVA-TRICOM or direct injection of MVA-TRICOM in patients with CLL has potential for the immunotherapy of CLL...
  77. ncbi A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1
    Kwong Yok Tsang
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:2139-49. 2004
    ....
  78. ncbi Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen
    Hiroshi Terasawa
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 8:41-53. 2002
    ..1/K(b) transgenic mice. These studies thus demonstrate the potential use of the PSA-3A agonist epitope in both peptide- and vector-mediated immunotherapy protocols for prostate cancer...
  79. ncbi Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination
    David A Zaharoff
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, United States
    Vaccine 25:2085-94. 2007
    ..These mechanistic studies, taken together with the enhancement of a vaccine response, demonstrate that chitosan is a promising and safe platform for parenteral vaccine delivery...
  80. ncbi Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens
    Claudia Palena
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cytokine 24:128-42. 2003
    ..ELISPOT and ELISA assays for lymphotactin confirmed and extended these findings. These studies suggest a potential role for lymphotactin in the T-cell activation processes and subsequent anti-tumor events...
  81. ncbi IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity
    Mary T Litzinger
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 110:3192-201. 2007
    ....
  82. ncbi Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction
    Zohreh Tatari-Calderone
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 169:6162-9. 2002
    ..Moreover, we demonstrate that T cells that have acquired CD80 have the ability to stimulate other T cells. These data thus suggest that CD80 acquisition by human T cells might play a role in the immunoregulation of T cell responses...
  83. ncbi Impact of tumour volume on the potential efficacy of therapeutic vaccines
    J L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U S A
    Curr Oncol 18:e150-7. 2011
    ....
  84. ncbi Molecular cloning and characterization of the complementary DNA of an M(r) 110,000 antigen expressed by human gastric carcinoma cells and upregulated by gamma-interferon
    S Shimada
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
    Cancer Res 54:3831-6. 1994
    ..Thus, the M(r) 110,000 molecule represents a potentially novel cell membrane glycoprotein whose possible role in human cancer and/or as a gamma-interferon-inducible gene product warrants further investigation...
  85. ncbi The use of monoclonal antibody B72.3 in the management of gynecologic malignancies
    J Simpson
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD 20892
    Yale J Biol Med 61:351-66. 1988
    ..These studies indicate the potential utility of MAb B72.3 in the diagnosis of gynecologic carcinoma...
  86. ncbi In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates
    D E Milenic
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, The National Institutes of Health, 9000 Rockville Pike, Bld. 10 Room B3B69, Bethesda, MD 20892, USA
    Cancer Biother Radiopharm 16:133-46. 2001
    ..The results described herein suggest that either of the cyclohexyl derivatives of DTPA may be suitable candidates for the labeling of immunoconjugates with alpha-emitting bismuth isotopes for radioimmunotherapeutic applications...
  87. ncbi Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
    John L Marshall
    Lombardi Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 23:720-31. 2005
    ..We describe here the first trial in humans of the CEA-TRICOM vaccines (also including an enhancer agonist epitope within the CEA gene)...
  88. ncbi Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:3017-24. 2005
    ..To determine the safety and immunologic and clinical efficacy of a dendritic cell vaccine modified to hyperexpress costimulatory molecules and tumor antigen...
  89. ncbi Physiological relevance of antigen presentasome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4+ T cells in the absence of APCs
    Jun Zhou
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA
    Blood 105:3238-46. 2005
    ....
  90. ncbi International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?
    Filippo Belardelli
    Istituto Superiore di Sanita, Rome, Italy
    Cancer Res 64:6827-30. 2004
    ..An entire session was devoted to the use of dendritic cells for the development of cancer vaccines. The results of clinical studies and the advantages of using new modalities for preparing dendritic cell-based vaccines were discussed...
  91. ncbi Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors
    Howard L Kaufman
    Tumor Immunology Laboratory, Department of Surgery, Columbia University, New York, NY 10032, USA
    Hum Gene Ther 17:239-44. 2006
    ....
  92. ncbi Chitosan solution enhances the immunoadjuvant properties of GM-CSF
    David A Zaharoff
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, United States
    Vaccine 25:8673-86. 2007
    ..We conclude that chitosan solution is a promising delivery platform for the sustained, local delivery of rGM-CSF...
  93. ncbi Acquisition of antigen presentasome (APS), an MHC/costimulatory complex, is a checkpoint of memory T-cell homeostasis
    Sven Mostbock
    The Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 109:2488-95. 2007
    ..The acquisition of APS by memory T cells might be an important checkpoint leading to the clonal deletion of the majority of effector T cells, possibly allowing the surviving cells to become long-term memory cells by default...
  94. ncbi Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4)
    Junko Yokokawa
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD
    Int J Cancer 121:595-605. 2007
    ..The studies reported here are the first to describe a PAGE4 CTL epitope and its agonist epitope, and thus identify PAGE4 as a potentially useful target for vaccine-mediated therapy of prostate cancer...
  95. ncbi The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Int J Gastrointest Cancer 32:1-6. 2002
    ..DC-based immunotherapy in this setting is safe and feasible and may lead to prolonged survival...
  96. ncbi Enhanced levels of costimulation lead to reduced effector/memory CD8+ T cell functionality
    Sven Mostbock
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 179:3524-34. 2007
    ..This compromised effector function of effector/memory CD8+ T cells in response to high levels of costimulation can have important implications for designing immunotherapeutic strategies to enhance immune responses...